Evidence map›Paper›PMID 35359406›Full record

ArticleFrontiers in oncology2022

Chemical Biology Screening Identifies a Vulnerability to Checkpoint Kinase Inhibitors in TSC2-Deficient Renal Angiomyolipomas.

Robert M Vaughan, Jennifer J Kordich, Chun-Yuan Chan, Nanda K Sasi, Stephanie L Celano, Kellie A Sisson, Megan Van Baren, Matthew G Kortus, Dean J Aguiar, Katie R Martin and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Robert M VaughanPediatrics and Human Development, College of Human Medicine, Michigan State University, Grand Rapids, MI, United States.
Jennifer J KordichCenter for Cancer & Cell Biology, Van Andel Research Institute, Grand Rapids, MI, United States.
Chun-Yuan ChanCenter for Cancer & Cell Biology, Van Andel Research Institute, Grand Rapids, MI, United States.
Nanda K SasiGraduate Program in Genetics, Michigan State University, East Lansing, MI, United States.
Stephanie L CelanoCenter for Cancer & Cell Biology, Van Andel Research Institute, Grand Rapids, MI, United States.
Kellie A SissonCenter for Cancer & Cell Biology, Van Andel Research Institute, Grand Rapids, MI, United States.
Megan Van BarenCenter for Cancer & Cell Biology, Van Andel Research Institute, Grand Rapids, MI, United States.
Matthew G KortusCenter for Cancer & Cell Biology, Van Andel Research Institute, Grand Rapids, MI, United States.
Dean J AguiarPreclinical Research, Tuberous Sclerosis Complex (TSC) Alliance, Silver Springs, MD, United States.
Katie R MartinCenter for Cancer & Cell Biology, Van Andel Research Institute, Grand Rapids, MI, United States.
Jeffrey P MacKeiganPediatrics and Human Development, College of Human Medicine, Michigan State University, Grand Rapids, MI, United States.
Van Andel Institute · USGrand Rapids Community College · USMichigan State University · USTSC Alliance · US

Funding

Therapeutic potential of targeting DNA repair deficiency in TSCR21CA263133 · NCI · MICHIGAN STATE UNIVERSITY · PI MACKEIGAN, JEFFREY PAUL · 2021 to 2022
$399k
Characterizing genetic modifiers in tumor burden of Tuberous Sclerosis ComplexK00CA245821 · NCI · MICHIGAN STATE UNIVERSITY · PI VAUGHAN, ROBERT MARK · 2021 to 2024
$374k
NCI NIH HHS K00 CA245821NCI NIH HHS R21 CA263133
6 · The paper itself

Abstract

The tuberous sclerosis complex (TSC) is a rare genetic syndrome and multisystem disease resulting in tumor formation in major organs. A molecular hallmark of TSC is a dysregulation of the mammalian target of rapamycin (mTOR) through loss-of-function mutations in either tumor suppressor

Indexed as

AZD7762checkpoint kinase inhibitorsCHEK1/2Chk1/2mTORTSC2tuberous sclerosis complextumor xenografts

Identifiers

PMID35359406
PMCPMC8960247
OpenAlexW4221097273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.